STZ
40
-2
TGNA
53
3
OI
30
5
PEP
33
-3
HCP
54
-2
PVH
59
-3
CMA
48
2
USB
53
3
ADBE
55
4
EW
57
2
ED
42
2
KO
44
-2
NEE
42
-2
KEY
30
3
BIIB
42
2
MMM
40
3
DNB
58
2
AES
49
-2
PSX
29
2
UNM
70
2
STZ
40
-2
TGNA
53
3
OI
30
5
PEP
33
-3
HCP
54
-2
PVH
59
-3
CMA
48
2
USB
53
3
ADBE
55
4
EW
57
2
ED
42
2
KO
44
-2
NEE
42
-2
KEY
30
3
BIIB
42
2
MMM
40
3
DNB
58
2
AES
49
-2
PSX
29
2
UNM
70
2
Financhill
Back

Aligos Therapeutics 10K Form

Buy
65

ALGS
Aligos Therapeutics

Last Price:
$43.14
Seasonality Move:
-16.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALGS News And Ratings

See the #1 stock for the next 7 days that we like better than ALGS

ALGS Financial Statistics

Sales & Book Value

Annual Sales: $15.5M
Cash Flow: $-20.1M
Price / Cash Flow: 0
Annual Sales: $15.07
Price / Book: 3.11

Profitability

EPS (TTM): -17.10530
Net Income (TTM): $-77M
Gross Margin: --
Return on Equity: -118.75%
Return on Assets: -68.4%

Aligos Therapeutics Earnings Forecast

Key Aligos Therapeutics Financial Ratios

  • The Research & Development expenses have been 470.35% of Revenue.
  • The Net Earning history of ALGS is -564.61% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 3 years.

Aligos Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALGS
Website: aligos.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.81
Quick Ratio: 3.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALGS Technical Analysis vs Fundamental Analysis

Buy
65
Aligos Therapeutics (ALGS) is a Buy

Is Aligos Therapeutics a Buy or a Sell?